Phase 1 pilot study of RRx-001+nivolumab in advanced metastatic cancer (PRIMETIME)

JOURNAL FOR IMMUNOTHERAPY OF CANCER(2019)

引用 0|浏览10
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要